Abstracts tagged "Adult-onset Still’s disease and tocilizumab"

Abstract Number: 253 • 2016 ACR/ARHP Annual Meeting
Corticosteroid-Free Tocilizumab Monotherapy for Adult Onset Still’s Disease: Results in Six Month
Tsuneo Kondo¹, Yusuke Okada², Akiko Shibata¹, Kentaro Chino¹, Ayumi Okuyama¹, Hirofumi Takei¹ and Koichi Amano¹, ¹Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ²Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
Background/Purpose: To assess the efficacy and safety of tocilizumab (TCZ) monotherapy for the induction therapy of adult onset Still’s disease (AOSD) in a prospective, single-arm, single-center, cohort,…
Abstract Number: 266 • 2015 ACR/ARHP Annual Meeting
Effect of Tocilizumab on Adults Onset Still’s Disease in Korean Population: Multicenter Retrospecitve Study of 24 Cases
Seung Taek Song¹, Jin Ju Kim², Seung Lee¹, Hye-Jin Jeong¹, Il Woong Sohn², Sung Won Lee², Joo Hyun Lee³, Hyoun-Ah Kim⁴, Kwang-Hoon Lee⁵, Sang Tae Choi⁶, Eun Young Lee⁷, Kichul Shin⁸, Hoon-Suk Cha⁹ and Dae-Hyun Yoo¹⁰, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Department of Rheumatology, Ilsan Paik Hospital, Inje University, Goyang, South Korea, ⁴Ajou University Hospital, Suwon, South Korea, ⁵Dongguk University Ilsan Hospital, Goyang, South Korea, ⁶Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea, ⁷Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁸Seoul National University College of Medicine, Seoul, South Korea, ⁹Division of Rheumatology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ¹⁰Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Adult onset Still’s disease (AOSD) is a rare inflammatory disorder of unknown etiology. Nonsteroidal anti-inflammatory drugs or corticosteroids are first-line drugs for treating AOSD.…
Abstract Number: 1241 • 2014 ACR/ARHP Annual Meeting
Efficacy of Tocilizumab Therapy in Korean Patients with Adults Onset Still’s Disease: Multicenter Retrospective Study of 20 Cases
Jin Ju Kim¹, Joo Hyun Lee², Chang-Nam Son³, Hyoun-Ah Kim⁴, Kwang-Hoon Lee⁵, Sang Tae Choi⁶, Eun Young Lee⁷, Ki Chul Shin⁸, Hoon-Suk Cha⁹ and Dae-Hyun Yoo¹, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Department of Rheumatology, Ilsan Paik Hospital, Inje University, Goyang, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea, ⁴Department of Rheumatology, Ajou University School of Medicine, Suwan, South Korea, ⁵Dongguk University Ilsan Hospital, Goyang, South Korea, ⁶Rheumatology, Chung-Ang University College of Medicine, Seoul, South Korea, ⁷Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁸Rheumatology, Seoul National University College of Medicine, Seoul, South Korea, ⁹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose Adult onset Still’s disease (AOSD) is a rare inflammatory disorder of unknown etiology. Refractory cases to conventional therapy require biologic agents. Although IL-1 targeting…
Abstract Number: 193 • 2012 ACR/ARHP Annual Meeting
Tocilizumab in Adult Still’s Disease : The Israeli Experience
Ori Elkayam¹, Nizar Jiries², Zvi Dranitzki³, Shaye Kivity⁴, Merav Lidar⁵, Ofer Levy⁶, Mahmoud Abu-Shakra⁷, Hagit Sarvagil-Maman⁸, Hagit Padova⁸, Dan Caspi⁹ and Itzhak Rosner¹⁰, ¹Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel- Aviv, Israel, ²Rheumatology, Bnai Zion Medical Center, Israel, ³Medicine, Hadassah hebrew university, Jerusalem, Israel, ⁴Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affliated to Sackler Faculty of Medicine, Tel-Aviv University Israel, Tel-Aviv, Israel, ⁵Medicine F, Sheba Medical Center, Ramat Gan, Israel, ⁶Rheumatology, Asaf Harofe Medical Center, ⁷Medicine and Rheumatology, Soroka Medical Centre and Ben Gurion University, Beer-Sheva, Israel, ⁸Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁹Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ¹⁰Rheumatology, Bnai Zion Medical Center / Technion Faculty of Medicine, Haifa, Israel
Background/Purpose: The objective of this study was to review the clinical and laboratory characteristics of patients with adult's Still disease treated with tocilizumab (TCZ) in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].